Ofatumumab in the treatment of non-Hodgkin’s lymphomas

Abstract

Introduction: Ofatumumab is a second-generation humanized monoclonal antibody targeting CD20 registered for the treatment of patients with relapsing/refractory chronic lymphocytic leukemia. This review will describe the activity of ofatumumab in patients with CD20 B-cell lymphomas.

Areas covered: A review of all manuscript published on ofatumumab activity in B-cell lymphomas is presented with conclusions on the future use of this antibody in these patients.

Expert opinion: Ofatumumab activity is low in indolent or aggressive B-cell lymphomas. The future of this drug is challenged by new monoclonal antibodies and new targeted drugs.

Keywords:

• diffuse large B-cell lymphoma
• follicular lymphoma
• ofatumumab

Declaration of interest

B Coiffier has been a part of advisory boards for Roche, Gilead, Pharmacyclics, TEVA, AstraZeneca, Celgene, Celltrion, MundiPharma, Novartis and Takeda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.